###### 

Quality assessment of selected RCTs according to the Cochrane Risk of Bias Assessment.

                            MAPPET (Konstantinides, 2002)   TIPES (Becattini, 2010)   Fasullo (Fasullo S, 2011)   TOPCOAT (Kline JA, 2014)   PEITHO (Meyer, 2014)   Sinha (Sinha SK, 2017)
  ------------------------- ------------------------------- ------------------------- --------------------------- -------------------------- ---------------------- ------------------------
  Sequence generation       Low risk                        Unclear                   Low risk                    Low risk                   Low risk               Unclear risk
                                                                                                                                                                    
  Allocation concealment    Unclear risk                    Unclear                   Unclear                     Low risk                   Low risk               Unclear risk
                                                                                                                                                                    
  Blinding                  Low risk                        Unclear risk              Low-risk                    Low risk                   Low risk               High risk
                                                                                                                                                                    
  Incomplete outcome data   Low risk                        Unclear risk              Low risk                    Unclear risk               Low risk               Low risk
                                                                                                                                                                    
  Selective reporting       Low risk                        Low risk                  Low risk                    Low risk                   Low risk               Low risk
                                                                                                                                                                    

###### 

Summary of selected studies.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Study & reference**                                                                                                                                                                                                                                                                              **Design & Size**              **Inclusion criteria**                                                  **Intervention & control**
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------ ----------------------------------------------------------------------- ------------------------------------
  **1. MAPPET**                                                                                                                                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                            

  Konstantinides, Geibel A, Heusel G,\                                                                                                                                                                                                                                                               \- RCT - Double-blind - 275    \- Symptoms less than\                                                  **Thrombolysis:**\
  Heinrich F, Kasper W. Heparin plus\                                                                                                                                                                                                                                                                                               96 hours & SBP\                                                         Alteplase100 mg\
  alteplase compared with heparin alone\                                                                                                                                                                                                                                                                                             ≥ 90 mmHg - RVD based on echo or ECG\                                  IV (10 mg bolus\
  in patients with submassive pulmonary\                                                                                                                                                                                                                                                                                            or PH on right side\                                                    followed by\
  embolism. N Engl J Med.\                                                                                                                                                                                                                                                                                                          catheterization                                                         90 mg over\
  2002;347(15):1143-50.                                                                                                                                                                                                                                                                                                                                                                                     2 hours) Control: placebo

                                                                                                                                                                                                                                                                                                                                                                                                            

  **2. TIPES**                                                                                                                                                                                                                                                                                                                                                                                              

                                                                                                                                                                                                                                                                                                                                                                                                            

  Becattini C, Agnelli G, Salvi A, Grifoni S, Pancaldi L,\                                                                                                                                                                                                                                           \- RCT - Double-blind - 58     \- Symptoms within 10 days\                                             **Thrombolysis:**\
  Enea I, et al. Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. Thromb Res. 2010;125(3):e82-6.                                                                                                                                                                      & SBP ≥ 100 mmHg - RVD at echocardiography                              Tenecteplase\
                                                                                                                                                                                                                                                                                                                                                                                                            30--50 mg\
                                                                                                                                                                                                                                                                                                                                                                                                            (weight adjusted) Control: placebo

                                                                                                                                                                                                                                                                                                                                                                                                            

  **3. Fasullo**                                                                                                                                                                                                                                                                                                                                                                                            

                                                                                                                                                                                                                                                                                                                                                                                                            

  Fasullo S, Scalzo S, Maringhini G, Ganci F, Cannizzaro S, Terrazzino G, et al. Six-month echocardiographic study in patients with submassive pulmonary embolism and right ventricle dysfunction: comparison of thrombolysis with heparin. Am J Med Sci. 2011;341(1):33-9.                          \- RCT - Double-blind - 78     \- Symptoms within 6 hours & SBP ≥ 100 mmHg - RVD at echocardiography   **Thrombolysis:**\
                                                                                                                                                                                                                                                                                                                                                                                                            Alteplase 10 mg\
                                                                                                                                                                                                                                                                                                                                                                                                            bolus, plus 90 mg\
                                                                                                                                                                                                                                                                                                                                                                                                            over 2 hours Control: placebo

                                                                                                                                                                                                                                                                                                                                                                                                            

  **4. TOPCOAT**                                                                                                                                                                                                                                                                                                                                                                                            

                                                                                                                                                                                                                                                                                                                                                                                                            

  Kline JA, Nordenholz KE, Courtney DM, Kabrhel C, Jones AE, Rondina MT, et al. Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at 3 months: multicenter double-blind, placebo-controlled randomized trial. J Thromb Haemost. 2014;12(4):459-68.   \- RCT - Double-blind - 83     \- Symptoms within 24 hours & SBP ≥ 100 mmHg - Hypokinesis on echo,\    **Thrombolysis:**\
                                                                                                                                                                                                                                                                                                                                    elevated troponin or BNP                                                Tenecteplase\
                                                                                                                                                                                                                                                                                                                                                                                                            30--50 mg\
                                                                                                                                                                                                                                                                                                                                                                                                            (weight adjusted) Control: placebo

                                                                                                                                                                                                                                                                                                                                                                                                            

  **5. PEITHO**                                                                                                                                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                            

  Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Eng J Med. 2014;370(15):1402-11.                                                                                                              \- RCT - Double-blind - 1006   \- Symptoms within 15 days\                                             **Thrombolysis:**\
                                                                                                                                                                                                                                                                                                                                    & SBP ≥ 100 mmHg - RVD confirmed by echo or\                            Tenecteplase\
                                                                                                                                                                                                                                                                                                                                    CT and or positive troponin\                                            30--50 mg\
                                                                                                                                                                                                                                                                                                                                    test                                                                    (weight adjusted) Control: placebo

                                                                                                                                                                                                                                                                                                                                                                                                            

  **6. Sinha**                                                                                                                                                                                                                                                                                                                                                                                              

                                                                                                                                                                                                                                                                                                                                                                                                            

  Sinha SK, Sachan M, Goel A, Singh K, Mishra V, Jha MJ, et al. Efficacy and Safety of Thrombolytic Therapy in Acute Submassive Pulmonary Embolism: Follow-Up Study. J Cli Med Res. 2017;9(2):163-169.                                                                                               \- RCT - Unblinded - 87        \- Symptoms within 15 days\                                             **Thrombolysis:**\
                                                                                                                                                                                                                                                                                                                                    & SBP ≥ 90 mmHg - RVD confirmed by echo or\                             Tenecteplase\
                                                                                                                                                                                                                                                                                                                                    CT and or positive troponin\                                            30--50 mg\
                                                                                                                                                                                                                                                                                                                                    test                                                                    (weight adjusted) Control: placebo

                                                                                                                                                                                                                                                                                                                                                                                                            
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Results of the pulmonary emboli studies.

  -----------------------------------------------------------------------------------------------------------------------------------------
                **Mortality outcomes**    **Major bleeding outcomes**   **Minor bleeding outcomes**   **Clinical deterioration outcomes**
  ------------- ------------------------- ----------------------------- ----------------------------- -------------------------------------
  **MAPPET**    Thrombolysis 4/118\       Thrombolysis\                 Not evaluated                 Thrombolysis 12/118\
                (3.4%) vs. placebo\       1/118(0.8%) vs.\                                            (10.2%) vs. placebo\
                3/138 (2.2%),\            placebo\                                                    34/138 (24.6%),\
                (p = 0.71)                5/138 (3.6%),\                                              (p = 0.004)
                                          (p = 0.29)                                                  

                                                                                                      

  **TIPES**     Thrombolysis 0/28 (0%)\   Thrombolysis 2/28\            Thrombolysis 13/28\           Thrombolysis\
                vs. placebo 1/30\         (7.14%) vs.\                  (46.42%) vs. placebo\         0/28(0%) vs.\
                (3.33%)                   heparin 1/30\                 1/30 (2.5%)                   placebo 1/30\
                                          (3.33%)                                                     (3.3%)

                                                                                                      

  **Fasullo**   Thrombolysis 0/37 vs.\    Thrombolysis 2/37\            Thrombolysis 11/37\           Not evaluated
                placebo 5/35\             (5.4%) vs. heparin\           (29.7%) vs. placebo\          
                (14.2%) (p = 0.055)       1/35 (2.85%)\                 4/35 (11.4%),\                
                                          (p: NS)                       (p = 0.20)                    

                                                                                                      

  **TOPCOAT**   Thrombolysis 1/40\        Thrombolysis 1/40\            Not evaluated                 Thrombolysis\
                (2.5%) vs. placebo\       (2.5%) vs. placebo\                                         0/40(0%) vs.\
                1/43 (2.32%)              0/43(0%)                                                    placebo\
                                                                                                      2/43 (4.65%)

                                                                                                      

  **PEITHO**    Thrombolysis 12/506\      Thrombolysis\                 Thrombolysis165/506\          Thrombolysis 8/506\
                (2.4%) vs. placebo\       58/506 (11.5%)\               (32.6%) vs. placebo\          (1.6) vs. placebo\
                16/499 (3.2%),\           vs. placebo\                  43/499 (8.6%)                 25/499 (5.0),\
                (p = 0.42)                12/499 (2.4%)                                               (p = 0.002)

                                                                                                      

  **Sinha**     Thrombolysis 2/45\        Thrombolysis 1/45\            Thrombolysis 7/45\            Thrombolysis 2/45\
                (4.5%) vs. placebo\       (2%) vs. placebo\             (16%) vs. placebo\            (4.5%) vs. placebo\
                2/41 (5%), (p = 0.3)      1/41 (2%),\                   5/41 (12%),\                  8/41 (20%),\
                                          (p = 0.45)                    (p = 0.04)                    (p = 0.04)

                                                                                                      
  -----------------------------------------------------------------------------------------------------------------------------------------
